February 01, 2015 6:19 PM ET


Company Overview of Sinapis Pharma, Inc.

Company Overview

Sinapis Pharma, Inc. operates as a clinical stage biotechnology company that develops Methamphetamine, an intravenous neuroprotective agent for treating stroke, traumatic brain injury, and other ischemic and traumatic conditions in patients. The company was founded in 2009 and is based in Jacksonville, Florida.

4350 Pablo Professional Court

Suite 200

Jacksonville, FL 32224

United States

Founded in 2009





Key Executives for Sinapis Pharma, Inc.

Chief Executive Officer
Age: 67
Founder and Chairman
Age: 53
Chief Scientific Officer
Age: 82
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Medicinal Genomics Corporation United States
Zor Pharmaceuticals LLC United States
CDI Laboratories, Inc. United States
Maxygen, Inc. United States
DEKALB Genetics Corporation United States

Recent Private Companies Transactions

Private Placement
September 19, 2014
Private Placement
April 9, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sinapis Pharma, Inc., please visit www.sinapispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.